American International Group, Inc. Uni Qure N.V. Transaction History

American International Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	SELL	$11.12 - $22.2 $3,102 - $6,193	-279 Reduced 10.7%	2,328 $26,000
Q1 2023 May 12, 2023	SELL	$18.7 - $23.07 $5,535 - $6,828	-296 Reduced 10.2%	2,607 $52,000
Q4 2022 Feb 10, 2023	SELL	$18.12 - $27.32 $1,793 - $2,704	-99 Reduced 3.3%	2,903 $65,000
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $5,416 - $8,147	319 Added 11.89%	3,002 $56,000
Q2 2022 Aug 12, 2022	SELL	$13.15 - $20.45 $933 - $1,451	-71 Reduced 2.58%	2,683 $50,000
Q1 2022 May 13, 2022	SELL	$14.54 - $21.5 $101 - $150	-7 Reduced 0.25%	2,754 $50,000
Q4 2021 Feb 11, 2022	SELL	$20.24 - $36.01 $2,489 - $4,429	-123 Reduced 4.26%	2,761 $57,000
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $75,012 - $110,226	2,884 New	2,884 $92,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $266M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.